Clinical trial
A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies
NCT00055263 · Novacea, Industry · Completed
Key facts
| NCT number | NCT00055263 |
|---|---|
| Title | A New Formulation of Calcitriol (DN-101) in Patients With Advanced Malignancies |
| Official title | A Phase I, Open Label, Dose Escalation Study of a New Formulation of Calcitriol (DN-101) for Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies |
| Lead sponsor | Novacea, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Neoplasms |
| Intervention type | Drug |
| Interventions | DN-101 |
| Enrollment | 60 |
| Start date | Mar 1, 2002 |
| First posted | Feb 25, 2003 |
| Last update posted | Jul 28, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: